Back to results
US 11,913,042 B2Granted
Methods for preparing and using highly active blood coagulation factor XI mutant and gene therapy/editing vector and recombinant/fusion protein thereof
AssigneesRuijin Hospital Shanghai Jiaotong University School of Medicine, Wenman Wu, Xuefeng Wang, Qiulan Ding
InventorsXuefeng Wang, Wenman Wu, Qiulan Ding
Life of this patent
Estimating the term…
Abstract
Methods of preparing and using a highly active blood coagulation factor XI mutant and a gene therapy/editing vector thereof and a recombinant/fusion protein thereof. The nucleotide sequence of the mutant is as shown in SEQ ID NOs: 1-6, and the amino acid sequence is as shown in SEQ ID NO: 7.
Claims5
A highly active blood coagulation factor XI nucleic acid, comprising:
- (1) the nucleotide sequence thereof is as shown in SEQ ID NO:
- 1, the nucleotide at position 1189 is A rather than G;
- or
- (2) the nucleotide sequence thereof is as shown in SEQ ID NO:
- 2, the nucleotide at position 1189 is A rather than G, and the nucleotide at position 1191 is C rather than T;
- or
- (3) the nucleotide sequence thereof is as shown in SEQ ID NO:
- 3, the nucleotide at position 1189 is T rather than G, and the nucleotide at position 1190 is C rather than G;
- or
- (4) the nucleotide sequence thereof is as shown in SEQ ID NO:
- 4, the nucleotide at position 1189 is T rather than G, the nucleotide at position 1190 is C rather than G, and the nucleotide at position 1191 is C rather than T;
- or
- (5) the nucleotide sequence thereof is as shown in SEQ ID NO:
- 5, the nucleotide at position 1189 is T rather than G, the nucleotide at position 1190 is C rather than G, and the nucleotide at position 1191 is A rather than T;
- or
- (6) the nucleotide sequence thereof is as shown in SEQ ID NO:
- 6, the nucleotide at position 1189 is T rather than G, the nucleotide at position 1190 is C rather than G, and the nucleotide at position 1191 is G rather than T.
14 more elements
A method for preparing a highly active blood coagulation factor XI protein, comprising the steps of:
- (1) inserting a human coagulation factor XI gene of human blood coagulation factor XI Gly397Ser mutant into a vector to obtain a recombinant vector;
- (2) transforming a host cell with the above recombinant vector to obtain a cell clone expressing the recombinant blood coagulation factor XI Gly397Ser mutant;
- (3) cultivating the above recombinant cell clone in a serum-free medium by continuous perfusion to induce expression of the recombinant blood coagulation factor XI Gly397Ser mutant protein;
- (4) performing isolation, purification, filtration, final filling and lyophilization to obtain the expressed highly active blood coagulation factor XI Gly397Ser mutant protein, wherein the position of the mutation is relative to the wild type human factor XI sequence of SEQ ID NO:
- 8.
2 more elements
Dependencies are inferred from the claim text.